Guangzhou LBP Medicine Science & Technology Co Ltd
SSE:688393
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Guangzhou LBP Medicine Science & Technology Co Ltd
Accrued Liabilities
Guangzhou LBP Medicine Science & Technology Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Guangzhou LBP Medicine Science & Technology Co Ltd
SSE:688393
|
Accrued Liabilities
¥31m
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Accrued Liabilities
¥197.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Accrued Liabilities
¥222.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Accrued Liabilities
¥2.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Andon Health Co Ltd
SZSE:002432
|
Accrued Liabilities
¥56.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Accrued Liabilities
¥922.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Guangzhou LBP Medicine Science & Technology Co Ltd
Glance View
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments. The company is headquartered in Guangzhou, Guangdong and currently employs 697 full-time employees. The company went IPO on 2020-08-20. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The firm operates its businesses within the domestic market and to overseas markets.
See Also
What is Guangzhou LBP Medicine Science & Technology Co Ltd's Accrued Liabilities?
Accrued Liabilities
31m
CNY
Based on the financial report for Dec 31, 2024, Guangzhou LBP Medicine Science & Technology Co Ltd's Accrued Liabilities amounts to 31m CNY.
What is Guangzhou LBP Medicine Science & Technology Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
15%
Over the last year, the Accrued Liabilities growth was -3%. The average annual Accrued Liabilities growth rates for Guangzhou LBP Medicine Science & Technology Co Ltd have been 5% over the past three years , 15% over the past five years .
